Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pain Crisis Clear all
Recruiting No phase listed Observational

Natural History of Sickle Cell Disease

NCT00081523
View directory record Official record
Conditions
Pain Crisis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 90 Years
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 12:36 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome

NCT02697240
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Intravenous citrulline
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
6 Years to 50 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 30, 2026, 12:36 AM EDT
Terminated Phase 3 Interventional

A Stratified Sickle Event Randomized Trial (ASSERT)

NCT00102791
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ICA-17043
Drug
Lead sponsor
Icagen
Industry
Eligibility
16 Years to 65 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
42
States / cities
Mobile, Alabama • Little Rock, Arkansas • Davis, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Oct 30, 2026, 12:36 AM EDT
Completed Phase 1Phase 2 Interventional

Intravenous Gammaglobulin for Sickle Cell Pain Crises

NCT01757418
View directory record Official record
Conditions
Sickle Cell Disease, Pain
Interventions
Immune Globulin Intravenous (IVIG), Normal saline
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
6 Years to 13 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 30, 2026, 12:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease

NCT01033227
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
sodium nitrite injection, usp
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
8 Years to 23 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 30, 2026, 12:36 AM EDT
Terminated Phase 2 Interventional

Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate

NCT00040456
View directory record Official record
Conditions
HEMOGLOBIN SC DISEASE
Interventions
Mg Pidolate, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 30, 2026, 12:36 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department

NCT02417298
View directory record Official record
Conditions
Pain, Sickle Cell Disorder
Interventions
Normal saline, Ketamine
Drug
Lead sponsor
Billy Sin
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 30, 2026, 12:36 AM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

NCT04912869
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crovalimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 30, 2026, 12:36 AM EDT
Recruiting Phase 2 Interventional

Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease

NCT06635902
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episode
Interventions
L-citrulline, Placebo
Drug · Other
Lead sponsor
Suvankar Majumdar
Other
Eligibility
4 Years to 21 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 30, 2026, 12:36 AM EDT
Completed Phase 2 Interventional Results available

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease

NCT01476696
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Prasugrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Oakland, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 30, 2026, 12:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Flow and Pain Crises in People With Sickle Cell Disease

NCT01568710
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 30, 2026, 12:36 AM EDT
Not listed Phase 2 Interventional

Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation

NCT00036712
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Oral Complications, Ovarian Cancer, Pain, Sarcoma
Interventions
management of therapy complications, pain therapy
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 30, 2026, 12:36 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

NCT05075824
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crovalimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Detroit, Michigan • Madison, Mississippi • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 30, 2026, 12:36 AM EDT
Withdrawn Phase 2 Interventional

Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis

NCT01932554
View directory record Official record
Conditions
Sickle Cell Disease, Hb-SS Disease With Vasoocclusive Pain, Hemoglobin SS Disease With Vasoocclusive Crisis, Other Sickle Cell Disease With Vaso-Occlusive Pain, Hemoglobin SS Disease With Crisis
Interventions
Abciximab, Placebo, Intravenous hydration, Ibuprofen, Parenteral narcotic, Incentive spirometry, Supplemental oxygen
Drug · Other
Lead sponsor
St. Louis University
Other
Eligibility
5 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 30, 2026, 12:36 AM EDT
Completed Phase 2 Interventional Results available

Pain Management in Children and Young Adults With Sickle Cell Disease

NCT01954927
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 20 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 30, 2026, 12:36 AM EDT
Completed Not applicable Interventional Results available

Hyperbaric Oxygen Therapy in Sickle Cell Pain

NCT03412045
View directory record Official record
Conditions
Vaso-occlusive Crisis, Sickle Cell Anemia Crisis
Interventions
hyperbaric oxygen therapy
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 12:36 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis

NCT04614610
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Crisis, Pain, Acute
Interventions
Lidocaine Iv, Placebo
Drug
Lead sponsor
Community Medical Center, Toms River, NJ
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Long Branch, New Jersey • New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 30, 2026, 12:36 AM EDT
Terminated Phase 1 Interventional Results available

Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency Department: Phase I

NCT01256281
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Femoral Nerve Block
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 30, 2026, 12:36 AM EDT
Terminated Phase 3 Interventional

A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

NCT05348915
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 30, 2026, 12:36 AM EDT
Completed No phase listed Observational

Quality of Life in Younger Leukemia and Lymphoma Survivors

NCT00956475
View directory record Official record
Conditions
Anxiety Disorder, Cancer Survivor, Fatigue, Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Lymphoma, Lymphoproliferative Disorder, Pain, Psychosocial Effects of Cancer and Its Treatment, Small Intestine Cancer
Interventions
telephone-based intervention, questionnaire administration, assessment of therapy complications, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Oct 30, 2026, 12:36 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

NCT02187003
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Rivipansel, Placebo
Drug · Other
Lead sponsor
Biossil Inc.
Industry
Eligibility
6 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
126
States / cities
Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 30, 2026, 12:36 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

NCT04935879
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Inclacumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 30, 2026, 12:36 AM EDT
Withdrawn Phase 4 Interventional

Ketamine Infusion for Sickle Cell Pain Crisis

NCT04005209
View directory record Official record
Conditions
Anemia; Sickle-Cell, With Crisis, Acute Pain
Interventions
Ketamine, Pain management
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 30, 2026, 12:36 AM EDT
Completed Phase 1 Interventional

Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease

NCT00095472
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
L-NMMA, Sodium Nitrite
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 30, 2026, 12:36 AM EDT